2011
Telomerase expression and telomere length in breast cancer and their associations with adjuvant treatment and disease outcome
Lu L, Zhang C, Zhu G, Irwin M, Risch H, Menato G, Mitidieri M, Katsaros D, Yu H. Telomerase expression and telomere length in breast cancer and their associations with adjuvant treatment and disease outcome. Breast Cancer Research 2011, 13: r56. PMID: 21645396, PMCID: PMC3218945, DOI: 10.1186/bcr2893.Peer-Reviewed Original ResearchConceptsEndocrine therapyDisease outcomeAdjuvant treatmentTelomerase expressionBetter survival outcomesDisease-free survivalHormone receptor statusBreast cancer patientsRisk of deathTelomere lengthHigh telomeraseCause-specific mortalityBreast cancer prognosisBreast cancer cellsCancer cell resistanceHigh telomerase expressionOverall survivalPatient ageDisease recurrenceReceptor statusHistological typeAggressive diseaseSurvival outcomesDisease stageCancer patients
2009
Molecular markers and death from prostate cancer.
Concato J, Jain D, Uchio E, Risch H, Li WW, Wells CK. Molecular markers and death from prostate cancer. Annals Of Internal Medicine 2009, 150: 595-603. PMID: 19414838, DOI: 10.7326/0003-4819-150-9-200905050-00005.Peer-Reviewed Original ResearchConceptsProstate-specific antigen levelProstate cancerLong-term riskAntigen levelsMicrovessel densityMedian prostate-specific antigen levelIncreased long-term riskVeterans Affairs Healthcare SystemIncident prostate cancerObservational cohort studyProportional hazards analysisTime of diagnosisHigher microvessel densityVeterans Health AdministrationBcl-2Years of ageProstate cancer biopsiesClinical care recordsClinical characteristicsCohort studyPatient ageMedian ageComorbid conditionsHistologic gradeResidual confounding